# Phase 1 neuroblastoma trials recruiting: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 1 for neuroblastoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 neuroblastoma trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/neuroblastoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07897968 | GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors | Universität Münster | Phase 1 | Not yet recruiting | Neuroblastoma (NBL), Ewing Sarcoma, Osteosarcoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897968) |
| July 7, 2026 | NCT07688252 | Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma | Chang Gung Memorial Hospital | Phase 1 | Recruiting | High Risk Neuroblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688252) |
| May 13, 2026 | NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors | Sun Yat-sen University | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584499) |
| April 8, 2026 | NCT07518654 | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic, Leukaemia... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518654) |
| January 22, 2026 | NCT07358260 | B7-H3.CD28Z.CART in Solid Tumors | Sponsor not shown (see the record) | Phase 1 | Recruiting | Pediatric Solid Tumor, Neuroblastoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358260) |
| October 8, 2025 | NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | Baylor College of Medicine | Phase 1 | Recruiting | Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211737) |
| September 15, 2025 | NCT07172958 | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) | Children's National Research Institute | Phase 1 | Recruiting | Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172958) |
| June 18, 2025 | NCT07027748 | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07027748) |
| May 30, 2025 | NCT06995872 | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma | National Cancer Institute (NCI) | Phase 1 | Recruiting | Neuroblastoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06995872) |
| December 27, 2024 | NCT06751134 | Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma | Nanjing Children's Hospital | Phase 1 | Recruiting | Neuroblastoma, Recurrent, Refractory | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751134) |
| November 5, 2024 | NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06674265) |
| October 8, 2024 | NCT06631391 | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. | Sun Yat-sen University | Phase 1 | Recruiting | Neuroblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06631391) |
| July 15, 2024 | NCT06500819 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | Stanford University | Phase 1 | Recruiting | Neuroblastoma, Sarcoma, Osteosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06500819) |
| July 3, 2024 | NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma | Princess Maxima Center for Pediatric Oncology | Phase 1 | Recruiting | Neuroblastoma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06485947) |
| September 18, 2023 | NCT06041516 | A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06041516) |
| June 1, 2022 | NCT05400603 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed... | Emory University | Phase 1 | Recruiting | Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05400603) |
| May 21, 2021 | NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04897321) |
| April 8, 2021 | NCT04837547 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy | University of Florida | Phase 1 | Recruiting | Neuroblastoma, Diffuse Intrinsic Pontine Glioma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04837547) |
| March 16, 2020 | NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | New York Medical College | Phase 1 | Recruiting | Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma, Hepatoblastoma, Germ Cell Tumor | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04308330) |
| October 26, 2018 | NCT03721068 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Recruiting | Neuroblastoma, Osteosarcoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03721068) |
| July 24, 2015 | NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | University of Wisconsin, Madison | Phase 1 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02508038) |
| December 17, 2013 | NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or... | South Plains Oncology Consortium | Phase 1 | Recruiting | Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02013336) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 2 |
| Sun Yat-sen University | 2 |
| University of Florida | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| New York Medical College | 1 |
| Chang Gung Memorial Hospital | 1 |
| Baylor College of Medicine | 1 |
| Princess Maxima Center for Pediatric Oncology | 1 |
| University of Wisconsin, Madison | 1 |
| Children's National Research Institute | 1 |
| Stanford University | 1 |
| Universität Münster | 1 |
| Nanjing Children's Hospital | 1 |
| St. Jude Children's Research Hospital | 1 |
| Emory University | 1 |
| South Plains Oncology Consortium | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 3 |
| Canada | 1 |
| Taiwan | 1 |
| Iran | 1 |
| Netherlands | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Psychiatric hospitals in the United States](https://specstream.ai/data/businesses/psychiatric-hospitals/united-states)
- [Livestock feed and supply stores in the United States](https://specstream.ai/data/businesses/livestock-feed-and-supply-stores/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
- [Ceiling and roofing repair and companies in the United States](https://specstream.ai/data/businesses/ceiling-and-roofing-repair-and-companies/united-states)
